• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Gulfo Adele M. claimed ownership of 4,000 shares (SEC Form 3)

    1/31/25 4:05:03 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYRA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Gulfo Adele M.

    (Last) (First) (Middle)
    C/O TYRA BIOSCIENCES, INC.
    2656 STATE STREET

    (Street)
    CARLSBAD CA 92008

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/29/2025
    3. Issuer Name and Ticker or Trading Symbol
    Tyra Biosciences, Inc. [ TYRA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 4,000 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney.
    /s/ Ali D. Fawaz, Attorney-in-Fact 01/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TYRA

    DatePrice TargetRatingAnalyst
    5/21/2025$33.00Overweight
    Piper Sandler
    1/7/2025$28.00Buy
    UBS
    10/18/2024$22.00 → $31.00Neutral → Buy
    BofA Securities
    8/15/2024$33.00Overweight
    Piper Sandler
    12/15/2023$25.00 → $15.00Buy → Neutral
    BofA Securities
    6/30/2023$27.00Outperform
    Wedbush
    2/3/2023$17.00Outperform
    Oppenheimer
    6/23/2022$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $TYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Tyra Biosciences with a new price target

      Piper Sandler resumed coverage of Tyra Biosciences with a rating of Overweight and set a new price target of $33.00

      5/21/25 9:01:58 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Tyra Biosciences with a new price target

      UBS initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $28.00

      1/7/25 8:31:57 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences upgraded by BofA Securities with a new price target

      BofA Securities upgraded Tyra Biosciences from Neutral to Buy and set a new price target of $31.00 from $22.00 previously

      10/18/24 7:41:59 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Financials

    Live finance-specific insights

    See more
    • Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

      - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, ann

      10/24/24 6:21:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

      CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Ste

      10/23/24 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

      - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima

      3/1/23 7:00:00 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

      CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global ex

      1/29/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

      -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cance

      1/10/25 8:00:00 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

      - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30

      11/7/24 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $19,836,066 worth of shares (1,220,681 units at $16.25) (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      11/13/24 5:00:07 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Fuhrman Alan bought $151,954 worth of shares (9,500 units at $16.00), increasing direct ownership by 284% to 12,849 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      11/1/24 4:22:45 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Harris Todd was granted 1,241 shares, increasing direct ownership by 0.09% to 1,357,168 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      3/18/25 6:44:12 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Fuhrman Alan was granted 1,238 shares, increasing direct ownership by 10% to 14,087 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      3/18/25 6:44:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kjellson Nina S sold $74,324 worth of shares (5,401 units at $13.76) (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      2/7/25 4:43:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Tyra Biosciences Inc.

      8-K - Tyra Biosciences, Inc. (0001863127) (Filer)

      5/29/25 4:22:58 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Tyra Biosciences Inc.

      EFFECT - Tyra Biosciences, Inc. (0001863127) (Filer)

      5/19/25 12:15:16 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.

      SCHEDULE 13G - Tyra Biosciences, Inc. (0001863127) (Subject)

      5/14/25 4:05:29 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

      SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      12/6/24 9:30:49 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

      SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      11/19/24 9:31:34 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

      SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      11/14/24 5:47:01 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences to Participate at Upcoming Investor Conferences

      CARLSBAD, Calif., May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: Bank of America Global Healthcare Conference, May 13-15, 2025Format: Fireside chat and one-on-one investor meetingsPresentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PTLocation: Las Vegas, NVJefferies Global Healthcare Conference, June 3-5, 2025Format: One-on-one investor meetingsLocation: New York, NYUBS Biotech 1x1 Symposium, June 24,

      5/12/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

      - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif., May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress. "In 2025, we are focus

      5/8/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

      - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 - CARLSBAD, Calif., March 27, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today rep

      3/27/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care